The aim of the study was to compare the pharmacokinetics (PK), safety and tolerability of secukinumab with different devices for subcutaneous (s.c.) administration of 2 mL.
| INTRODUCTION
Secukinumab (Cosentyx) is a recombinant high-affinity fully human monoclonal anti-human interleukin-17A (IL-17A) antibody of the IgG1/κ isotype, approved for the treatment of moderate to severe psoriasis, ankylosing spondylitis and psoriatic arthritis. Secukinumab binds to human IL-17A and neutralizes the bioactivity of this cytokine. IL-17A is the central cytokine of a defined subset of inflammatory T cells, the Th17 cells which, in several animal models, are pivotal for several autoimmune and inflammatory processes. [1] [2] [3] The marketed therapeutic doses are available as lyophilized drug formulation and a 1-mL liquid formulation either as a 150-mg/mL prefilled syringe (PFS) or as a 150-mg/mL auto-injector (AI). [4] [5] [6] The highest marketed dose is 300 mg and currently 2 injections are required to achieve that dose.
Therefore, for the convenience of patients with potentially better compliance, alternative single-step options of administration were explored in the present studies and compared to the existing 150-mg AI and PFS administration forms.
Today, most biologics are administered by subcutaneous (s.c.) injection, commonly in volumes not exceeding 1-1.5 mL 7-9 and several recommendations limit the volume of s.c. injection to 1 mL. 10 However, there is no evidence to support this limitation in volume and some recent studies suggest that s.c. injection volumes up to 3 mL are well tolerated. [11] [12] [13] In a clinical study recently published by Heise et al 12 the authors analysed the role of multiple factors, i.e. injection volume (0.4-1.6 mL), injection site (abdomen or thigh) and injection rate (0.15 or 0.45 mL/s) on the tolerance of a s.c. injection of 0.9% saline solution. A major factor influencing subject tolerance, assessed using a 100-mm visual analogue scale (VAS), was pain at the injection site (both statistically and clinically significantly favouring abdomen over thigh). Pain intensity scores were statistically higher with larger volumes. Interestingly, injection rate did not play any role in subject tolerance. However, based on available data today (published and unpublished), it has not been possible to determine the maximum volume and viscosity that can be delivered during a 10-15 s injection with an AI and the impact of drug viscosity on subject tolerance, safety and pharmacokinetics. Although there is an increasing understanding of formulation parameters impacting the viscosity of formulations for monoclonal antibodies, it is not straightforward to develop a generic formulation strategy for concentrated monoclonal antibody formulations with low viscosity. 8, 13 In a study by Berteau et al. 11 it was counterintuitively observed that injection pain decreases with increase in the viscosity of the fluid injected. However, it was noted that this result needed additional confirmation using devices specifically adapted for injection of viscous solutions.
Therefore, it remains partially unclear if certain injection conditions, such as using a particular injection site, injection speed or volume can reduce discomfort and pain of injections. Due to dose requirements and formulation limitations, s.c. injections >1 mL are often required. The purpose of the phase 1 study as described in this paper was to assess the pharmacokinetics (PK), safety and tolerability after single s.c. administration of 300 mg secukinumab using 4 new 2 mL administration systems compared to both the existing 150-mg/1-mL AI device and the existing 150-mg/1-mL PFS.
In this study, the role of device with inherently different injection speeds, site (abdomen/thigh) and side (left/right) of the injection on the tolerance and pharmacokinetics of 2-mL s.c. injections of the monoclonal antibody secukinumab was investigated. Further, PK from a phase 3 study in moderate to severe psoriasis patients after multiple s.c. administrations of 300 mg secukinumab using a 2-mL PFS compared to the existing 150-mg/1-mL PFS are reported. To the best of our knowledge, these are the first comprehensive results for an approved monoclonal antibody with single 2-mL injection devices in healthy subjects and with multiple dose injections with a 2-mL PFS in psoriasis patients. single s.c. administration of secukinumab 300 mg. No prior information on variability in PK parameters between subjects existed for these new devices. However, previous PK results from proof of concept and dose finding studies suggested that a minimum planned total sample size of 120 subjects with 20 subjects per arm was sufficient to characterize the PK of the devices for secukinumab.
The 120 subjects were randomized to include 20 subjects in each of the 6 device arms with balance between site and side, and replacement of dropouts was allowed. The total duration of subject participation was up to 20 weeks, including: (i) a screening visit up to 28 days prior to injection; (ii) followed by a baseline visit and a subsequent single treatment visit; (iii) a follow-up period with a domiciled period in the study unit 1 day after injection; and (iv) an ambulatory period during which subjects returned to the study unit for scheduled visits from 2 to 112 days (16 weeks) after administration.
Healthy male and female subjects aged 18-65 years with a body weight between 50 and 90 kg and a body mass index within the range of 18-30 kg/m 2 were eligible. Subjects provided written informed consent before any protocol-specific procedure. All subjects were informed about the nature and purpose of the study, participation/termination conditions, and risks and benefits of treatment.
Use of any prescription drugs was prohibited, except for permitted use of oral/injectable contraception, herbal supplements within 4 weeks prior to initial dosing or over-the-counter medication or dietary supplements (vitamins included) within 2 weeks prior to initial dosing.
Eligible and consented subjects were admitted to the study centre for baseline evaluation and randomized if they met all the inclusion/exclusion criteria.
| Study objectives
The primary objective of this study was to characterize the PK of secukinumab 300 mg administered s.c. by 6 different devices. Secondary objectives included assessment of the tolerability and safety of 2-mL s.c. injections of secukinumab by these different administration methods. Exploratory objectives included the qualitative assessment of any leakage after 2-mL s.c. injections of secukinumab by these different administration systems, and comparison of the PK of secukinumab 300 mg when administered in the thigh or abdomen, or administered in the left or right side.
| Dosage and administration
Secukinumab was supplied as a sterile 150-mg solution provided in a 1-mL AI or in a PFS with an extractable volume of 1 mL for the 2 × 1-mL injections. For the 2-mL injections, auxiliary supplies were sourced locally or by Drug Supply Management of Novartis. Each subject received 300 mg of secukinumab. This dose was the highest assessed s.c. dose in psoriasis phase 3 studies, showed superior results in comparison to 150 mg and is the therapeutic dose level in psoriasis patients. 4 This 300-mg single dose was known to be safe and well tolerated in previous healthy volunteer studies.
Subjects were assigned to 1 of following 6 devices (treatment arms) in a ratio of 1:1:1:1:1:1 (aiming for 20 in each arm). The 6 study treatments are defined as:
A. Two injections of secukinumab 150 mg/mL, using two 1- An overview of the administration devices is given in Table 1 .
Furthermore, study subjects randomized to each individual device were also randomized to site of injection (thigh or abdomen) and side of injection (left or right), giving 5 subjects at each of the 4 possible combinations per device, and 30 overall. 
| Sample collections

| PK analysis
The PK parameters of secukinumab were determined using the actual recorded sampling times and noncompartmental method(s) with WinNonlin Phoenix (Version 6.2 and higher).
Concentrations below the LLOQ were treated as zero for PK parameter calculations. The derived pharmacokinetic parameters in the phase 1 study included the maximum observed serum concentration (C max ); time to reach C max (t max ); area under the serum-concentration curve (AUC) from time zero to time of last measured concentration (AUC last ); AUC from time zero to infinity (AUC inf ); terminal half-life (t 1/2 ); apparent clearance (CL/F); and apparent volume of distribution based on the terminal phase (V z / F). The linear trapezoidal rule was used for AUC calculation.
Regression analysis of the terminal serum elimination phase for the determination of t 1/2 included at least 3 data points after C max . If the R 2 -adjusted value of the regression analysis of the terminal phase was <0.75, no values were reported for t 1/2 , AUC inf , V z /F and CL/F. C max , t max and AUC 84-112d were derived in the phase 3 study.
| Statistical analysis
Descriptive statistics were used to summarize serum secukinumab concentrations at each scheduled sampling time point and to summarize the derived pharmacokinetic parameters of secukinumab. PK parameters were calculated and their descriptive summary statistics were mean (arithmetic and geometric), standard deviation and coefficient of variation (%CV; arithmetic and geometric), median, minimum and maximum. t max was an exception to this, where median, minimum and maximum were presented. The log-transformed parameters AUC last , AUC inf (phase 1 study only), AUC 84-112d (phase 3 study only), and C max were analysed by a linear model, with injection device as a fixed factor of primary interest and weight at baseline as covariate.
The effect of location of injection (site and side) was also explored.
For each of AUC last , AUC inf and C max , the mean estimate and 90% confidence interval (CI) for the PK parameter ratio of injection device vs PFS twice 1 mL in 10 s were reported to represent the relative bioavailability for comparison. The same was done for the AUC 84-112d ratio 2 × 1-mL PFS vs 2-mL PFS in the phase 3 study.
In the phase 1 study, over all treatment arms, half of the subjects received the administration either at the left or right side of the body (side effect) and half of them either in the thigh or in the abdomen (site effect) balanced over treatments in a factorial 6 × 2 × 2 fashion.
Therefore, the statistical analysis of PK and other parameters allowed to look at the main effect of side or site, as well as of the main study treatment, device, using all the data. PK parameters were analysed by a fixed effect model with terms bodyweight, treatment, site and side.
In the phase 3 study, side (left/right) and site (abdomen, thigh, shoulder) of every injection was documented, which allowed an evaluation of impact on serum exposure resulting from a specific injection.
| Safety and tolerability assessments in phase 1 study
All injections were monitored for reactions by rating severity (none, 
| PK
Among the 122 subjects enrolled in the study, 121 had evaluable sam- similar for the 6 devices as well. Mean elimination half-lives of secukinumab per device were in a narrow range between 28 and 33 days.
As for the other PK parameters, the apparent volumes of distribution and clearance did not show any dependence on the device used. V z /F ranged from 6.49 to 9.71 L, and Cl/F from 0.154 to 0.223 L/day. For all PK parameters, the intersubject variability was similar for the 6 devices, as shown by the CV values in Table 3 . CV% for the AUCs and C max ranged between 19.9 and 39.9%, between 15.1 and 23.9% for t 1/2 , and between 18.6 and 90.2% for Cl/F and V z /F. The higher CV% in the AI (2 × 1 mL) was due to 1 individual outlier profile with a very low C max <10 μg/mL and a Vz/F of 37.6 L and a Cl/F of 1.01 L/day. All tabulated PK parameters are provided in Table 3 .
| Statistical comparisons
As summarized in Table 4 , the geometric mean ratios (90% CI) for AUC inf , AUC last and C max for any of the 5 devices compared with PFS Exploratory objectives in this study included the comparison of PK parameters when 300 mg was administered in either the thigh or abdomen and either the left or right side. As can be seen in Table 5 , no difference between administrations at the left or right side was observed, whereas some evidence exists of a slightly elevated exposure combined with an earlier t max from thigh compared with abdomen.
| Immunogenicity
Immunogenicity data were collected at baseline and at the end of study visit. Treatment-emergent ADA (i.e. negative at baseline but positive after start of treatment) were detected in 2 subjects. Moderate induration and mild erythema were observed in 1 of these subjects on Day 1. Three subjects with ADA at baseline and a negative result at the end of the study were observed as well. No impact on PK or AEs was observed in any of these 5 subjects.
| Local tolerability
Local tolerability of the injection site was assessed by a clinical evaluation of erythema, induration and haemorrhage. Results are summarized in Table 6 . The significant P-value for erythema treatment differences overall is mainly due to its presence in 11/20 subjects using the SmartDose device with other devices having lower or no incidence. The AIs did not provoke any erythema. The high SmartDose incidence was probably linked to the patch system. Similarly, the syringe pump had the second highest incidence 
| Safety
There were no subjects discontinued from the study due to any safety reasons (AEs/severe AEs). A total of 29 subjects (23.8%) across the treatment groups experienced at least 1 AE during the study, a total of 44 nonserious AEs. The most frequently affected system organ class, which involved all subjects of the 6 device groups, was infections and infestations (11 AEs in 10 subjects, 8.2%). This included gastroenteritis (n = 1, 0.8%), viral influenza (n = 3, 2.5%), nasopharyngitis (n = 3, 2.5%), pharyngitis (n = 2, 1.6%), streptococcal sinusitis (n = 1, 0.8%) and upper respiratory tract infection (n = 1, 0.8%). Table 7 .
|
Mean C max , AUC 84-112d and median t max values were similar after either injection with 2 mL PFS or 2 × 1 mL PFS. The median t max of approximately 91 days was reported here as postdose timepoint after the first dose administration, which corresponds to approximately 7 days postdose after the Week 12 dose. The 90%
CIs for the ratio of geometric means for AUC 84-112d and C max , were all contained in the interval (0.80, 1.25), indicating that the 2 devices were comparable, see devices is in agreement with earlier observations. 15 After t max , the mean serum concentrations of secukinumab declined in an apparently mono-exponential manner, which was consistent with population PK models for secukinumab in patients with psoriasis. 15 The mean V z /F values were in the range between 6.5 and 9.7 L, which is also in line with the volume of distribution values reported in psoriasis patients. 15 With an absolute bioavailability of 73% in psoriasis patients, the mean V z is estimated to be in the range between 4.7 and 7.0 L, suggesting that secukinumab is primarily confined to the systemic circulation with limited extravascular tissue distribution. The PK observations as described above for the phase 1 study were confirmed in the phase 3 study in moderate to severe psoriasis patients. Serum exposure was similar after either injection of 300 mg as 2 × 1 mL in PFS or as a 16 For instance, exposure of human growth hormone (22 kDa) was found to be significantly higher after s.c. injection into the abdomen than after injection into the thigh. 17 For recombinant human erythropoietin (30 kDa), the opposite occurs, 18 although in another study with recombinant human erythropoietin, there were no significant differences between the abdomen and thigh injection sites. 19 Label text for the anti-IL-17A antibody, ixekizumab, states that "in studies of subjects with plaque psoriasis, ixekizumab bioavailability ranged from 60 to 81% following s.c. injection. Administration of ixekizumab via injection in the thigh achieved a higher bioavailability relative to that achieved using other injection sites including the arm and abdomen." 20 For secukinumab we seem to have a similar observation, which is also confirmed for other investigated monoclonal antibodies such as bococizumab, golimumab and mepolizumab; s.c. administration in the thigh consistently resulted in higher serum exposure compared to injections in the abdomen region. [21] [22] [23] [24] It is well acknowledged that the incomplete absorption of protein drugs, with absolute bioavailabilities ranging from 20 to 100%, is likely to be due to protein degradation in the region of the s.c. injection site as well as in lymphatic vessels during transport. It might be speculated that degree of protein degradation, transport time in lymphatic vessels and the protecting role of FcRn during transport differ to some extent between abdominal and thigh injection. However, taking the rather large interindividual variability of s.c. bioavailability of therapeutic proteins into account as well, it is reasonable to conclude that the effect of injection site on serum exposure is not clinically relevant.
As demonstrated in this study, the tolerability of 2-mL s.c.
injection of secukinumab 150-mg/mL formulation was good and not different between all 2-mL delivering devices. This is an important finding because of a widespread assumption that the upper limit for s.c. injection of a therapeutic protein is approximately 1 mL. Observations in the study by Heise et al 12 suggested that from a tolerability (pain) point of view, volumes up to 3 mL may be preferably injected in the abdomen, with worse tolerability in the thigh. At least for the 2-mL injections as described here, this could not be confirmed in our study; comparable VAS scores were obtained with abdominal and thigh injections and small differences were statistically not significant. Another interesting finding was the similar pain and general tolerance between the different rates of s.c. infusion with times to inject 2 mL varying between 10 s and 5 min. This basically confirms earlier findings described in literature that injection speed has little impact on injection pain and tolerance. 11, 12 It has to be noted here that for AIs it is recommended to have the injection completed within 10-15 s or even less, to minimize the risk of the patient performing an incomplete administration by withdrawing the AI too early, before completion of injection. Because of the devices used, pain due to needle penetration through the skin was not separately assessed.
However, as reported in several papers, 11, 12 pain recorded after needle insertion is usually similar to mean injection pain for volumes up to 3 mL. Pain due to needle penetration is mainly influenced by the needle gauge size. 18 Two cases of TE-ADA formation were observed. ADA formation was neither related to AEs potentially related with immunogenicity nor to deviating PK profiles.
T A B L E 8 Geometric means, estimated geometric mean ratio and 90% confidence interval (CI) for geometric ratio of pharmacokinetic (PK) parameters in psoriasis patients To the best of our knowledge, it was demonstrated for the first time for monoclonal antibodies that volumes of 2 mL, administered in a time range between 10 s and 5 min, are very well tolerated as a s.c.
administration.
While there is widespread belief that the upper limit for a given s.c. injection is approximately 1 mL (driven by injection tolerance), our study results suggest that the upper limit for a given s.c.
volume in the abdomen and thigh, merely based on injection tolerance, is well above 1 mL. As demonstrated, volumes of 2 mL were well tolerated. Regardless of the relatively large volume injected, the overall tolerance of the s.c. injections was good. It is interesting to note that the maximum injection pain measured using 100 mm VAS was in the range between 4.5 mm (SmartDose) and 12.9 mm (Twin-01) and was not clinically significantly higher (<10 mm) than the mean pain recorded after needle insertion. This suggests that a major component of the overall s.c. injection pain originates from the needle insertion alone. 11 In summary, no clinically relevant differences between 1-and 2-mL devices for s.c. administration of secukinumab were observed.
